Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 30

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Current application of CRISPR/Cas9 gene-editing technique to eradication of HIV/AIDS

Huang, Z, Tomitaka, A, Raymond, A, Nair, M·2017·Gene Therapy

Abstract

Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) remains a major health hazard despite significant advances in prevention and treatment of HIV infection. The major reason for the persistence of HIV/AIDS is the inability of existing treatments to clear or eradicate the multiple HIV reservoirs that exist in the human body. To suppress the virus replication and rebound, HIV/AIDS patients must take life-long antiviral medications. The clustered regularly interspaced palindromic repeats (CRISPR)/CRISPR-associated nuclease 9 (Cas9) system is an emerging gene-editing technique with the potential to eliminate or disrupt HIV-integrated genomes or HIV-infected cells from multiple HIV reservoirs, which could result in the complete cure of HIV/AIDS. Encouraging progress has already been reported for the application of the CRISPR/Cas9 technique to HIV/AIDS treatment and prevention, both in vitro in human patient cells and in vivo in animal model experiments. In this review, we will summarize the most recent progress in the application of the CRISPR/Cas9 gene-editing technique to HIV/AIDS therapy and elimination. Future directions and trends of such applications are also discussed.

Overview

Integrity signals

Registry

Crossref · 10.1038/gt.2017.35

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 17 references

Research works printed but not linked: 83

  1. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS . Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 1998; 188: 83–91. · DOI · Paper page
  2. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295–1300. · DOI · Paper page
  3. Bagasra O, Lavi E, Bobroski L, Khalili K, Pestaner JP, Tawadros R et al. Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry. AIDS 1996; 10: 573–585. · DOI · Paper page
  4. Fischer-Smith T, Croul S, Sverstiuk AE, Capini C, L'Heureux D, Regulier EG et al. CNS invasion by CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection. J Neurovirol 2001; 7: 528–541. · DOI · Paper page
  5. Petito CK, Chen H, Mastri AR, Torres-Munoz J, Roberts B, Wood C . HIV infection of choroid plexus in AIDS and asymptomatic HIV-infected patients suggests that the choroid plexus may be a reservoir of productive infection. J Neurovirol 1999; 5: 670–677. · DOI
  6. McElrath MJ, Steinman RM, Cohn ZA . Latent HIV-1 infection in enriched populations of blood monocytes and T cells from seropositive patients. J Clin Invest 1991; 87: 27–30. · doi:10.1172/jci114981
  7. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS . Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998; 95: 8869–8873. · DOI · Paper page
  8. Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008; 197: 714–720. · DOI · Paper page
  9. Smith PD, Meng G, Salazar-Gonzalez JF, Shaw GM . Macrophage HIV-1 infection and the gastrointestinal tract reservoir. J Leuko Biol 2003; 74: 642–649. · DOI
  10. Lambert-Niclot S, Peytavin G, Duvivier C, Poirot C, Algarte-Genin M, Pakianather S et al. Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy. Antimicrob Agents Chemother 2010; 54: 4910–4913. · DOI
  11. Cu-Uvin S, DeLong AK, Venkatesh KK, Hogan JW, Ingersoll J, Kurpewski J et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2010; 24: 2489–2497. · doi:10.1097/qad.0b013e32833e5043
  12. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15: 893–900. · DOI · Paper page
  13. Chun TW, Nickle DC, Justement JS, Large D, Semerjian A, Curlin ME et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 2005; 115: 3250–3255. · DOI · Paper page
  14. Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci USA 2014; 111: 2307–2312. · DOI · Paper page
  15. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65: 65–70. · DOI · Paper page
  16. Solas C, Lafeuillade A, Halfon P, Chadapaud S, Hittinger G, Lacarelle B . Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47: 238–243. · DOI · Paper page
  17. Heaton RK, Franklin DR Jr, Deutsch R, Letendre S, Ellis RJ, Casaletto K et al. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis 2015; 60: 473–480. · DOI · Paper page
  18. Churchill MJ, Wesselingh SL, Cowley D, Pardo CA, McArthur JC, Brew BJ et al. Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol 2009; 66: 253–258. · DOI · Paper page
  19. Ellis RJ, Rosario D, Clifford DB, McArthur JC, Simpson D, Alexander T et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol 2010; 67: 552–558. · DOI · Paper page
  20. Churchill MJ, Gorry PR, Cowley D, Lal L, Sonza S, Purcell DF et al. Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues. J Neurovirol 2006; 12: 146–152. · DOI · Paper page
  21. Narasipura SD, Kim S, Al-Harthi L . Epigenetic regulation of HIV-1 latency in astrocytes. J Virol 2014; 88: 3031–3038. · DOI
  22. Nath A . Eradication of human immunodeficiency virus from brain reservoirs. J Neurovirol 2015; 21: 227–234. · DOI
  23. Dampier W, Nonnemacher MR, Sullivan NT, Jacobson JM, Wigdahl B . HIV excision utilizing crispr/cas9 technology: attacking the proviral quasispecies in reservoirs to achieve a cure. MOJ Immunol 2014; 1: pii:00022.
  24. Kaminski R, Chen Y, Fischer T, Tedaldi E, Napoli A, Zhang Y et al. Elimination of HIV-1 genomes from human T-lymphoid cells by CRISPR/Cas9 gene editing. Sci Rep 2016; 6: 22555. · DOI · Paper page
  25. Saayman SM, Lazar DC, Scott TA, Hart JR, Takahashi M, Burnett JC et al. Potent and targeted activation of latent HIV-1 using the CRISPR/dCas9 activator complex. Mol Ther 2016; 24: 488–498. · DOI
  26. Zhang Y, Yin C, Zhang T, Li F, Yang W, Kaminski R et al. CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs. Sci Rep 2015; 5: 16277. · DOI · Paper page
  27. Chylinski K, Le Rhun A, Charpentier E . The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems. RNA Biol 2013; 10: 726–737. · DOI · Paper page
  28. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E . A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012; 337: 816–821. · DOI · Paper page
  29. Chavez L, Calvanese V, Verdin E . HIV latency is established directly and early in both resting and activated primary CD4 T cells. PLoS Pathog 2015; 11: e1004955. · DOI · Paper page
  30. Stanley SK, Ostrowski MA, Justement JS, Gantt K, Hedayati S, Mannix M et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996; 334: 1222–1230. · doi:10.1056/nejm199605093341903
  31. Brady T, Agosto LM, Malani N, Berry CC, O'Doherty U, Bushman F . HIV integration site distributions in resting and activated CD4+ T cells infected in culture. AIDS 2009; 23: 1461–1471. · DOI
  32. Schneider M, Tigges B, Meggendorfer M, Helfer M, Ziegenhain C, Brack-Werner R . A new model for post-integration latency in macroglial cells to study HIV-1 reservoirs of the brain. AIDS 2015; 29: 1147–1159. · DOI
  33. Sunshine S, Kirchner R, Amr SS, Mansur L, Shakhbatyan R, Kim M et al. HIV Integration site analysis of cellular models of HIV latency with a probe-enriched next-generation sequencing assay. J Virol 2016; 90: 4511–4519. · DOI
  34. du Chene I, Basyuk E, Lin YL, Triboulet R, Knezevich A, Chable-Bessia C et al. Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J 2007; 26: 424–435. · DOI · Paper page
  35. Gallastegui E, Millan-Zambrano G, Terme JM, Chavez S, Jordan A . Chromatin reassembly factors are involved in transcriptional interference promoting HIV latency. J Virol 2011; 85: 3187–3202. · DOI
  36. Barboric M, Nissen RM, Kanazawa S, Jabrane-Ferrat N, Peterlin BM . NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol Cell 2001; 8: 327–337. · DOI · Paper page
  37. Lenasi T, Contreras X, Peterlin BM . Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe 2008; 4: 123–133. · DOI · Paper page
  38. Huang J, Wang F, Argyris E, Chen K, Liang Z, Tian H et al. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med 2007; 13: 1241–1247. · DOI · Paper page
  39. Patel P, Ansari MY, Bapat S, Thakar M, Gangakhedkar R, Jameel S . The microRNA miR-29a is associated with human immunodeficiency virus latency. Retrovirology 2014; 11: 108. · doi:10.1186/s12977-014-0108-6
  40. Ruelas DS, Chan JK, Oh E, Heidersbach AJ, Hebbeler AM, Chavez L et al. MicroRNA-155 Reinforces HIV Latency. J Biol Chem 2015; 290: 13736–13748. · DOI
  41. Delagreverie HM, Delaugerre C, Lewin SR, Deeks SG, Li JZ . Ongoing clinical trials of human immunodeficiency virus latency-reversing and immunomodulatory agents. open forum. Infect Dis 2016; 3: ofw189.
  42. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487: 482–485. · DOI · Paper page
  43. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 2014; 1: e13–e21. · DOI · Paper page
  44. Wood AJ, Lo TW, Zeitler B, Pickle CS, Ralston EJ, Lee AH et al. Targeted genome editing across species using ZFNs and TALENs. Science 2011; 333: 307. · DOI · Paper page
  45. Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 2011; 29: 143–148. · DOI · Paper page
  46. Zhang F, Cong L, Lodato S, Kosuri S, Church GM, Arlotta P . Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol 2011; 29: 149–153. · DOI · Paper page
  47. Reyon D, Tsai SQ, Khayter C, Foden JA, Sander JD, Joung JK . FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol 2012; 30: 460–465. · DOI · Paper page
  48. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science 2007; 315: 1709–1712. · DOI · Paper page
  49. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013; 339: 819–823. · DOI · Paper page
  50. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE et al. RNA-guided human genome engineering via Cas9. Science 2013; 339: 823–826. · DOI · Paper page
  51. Hsu PD, Lander ES, Zhang F . Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014; 157: 1262–1278. · DOI · Paper page
  52. Shi B, Li J, Shi X, Jia W, Wen Y, Hu X et al. TALEN-mediated knockout of CCR5 confers protection against infection of human immunodeficiency virus. J Acquir Immune Defic Syndr 2016. · DOI
  53. Strong CL, Guerra HP, Mathew KR, Roy N, Simpson LR, Schiller MR . Damaging the Integrated HIV Proviral DNA with TALENs. PloS One 2015; 10: e0125652. · DOI
  54. Anders C, Niewoehner O, Duerst A, Jinek M . Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature 2014; 513: 569–573. · DOI · Paper page
  55. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F . Genome engineering using the CRISPR-Cas9 system. Nat Protoc 2013; 8: 2281–2308. · DOI · Paper page
  56. Hou P, Chen S, Wang S, Yu X, Chen Y, Jiang M et al. Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci Rep 2015; 5: 15577. · DOI · Paper page
  57. Schumann K, Lin S, Boyer E, Simeonov DR, Subramaniam M, Gate RE et al. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci USA 2015; 112: 10437–10442. · DOI · Paper page
  58. Ye L, Wang J, Beyer AI, Teque F, Cradick TJ, Qi Z et al. Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Delta32 mutation confers resistance to HIV infection. Proc Natl Acad Sci USA 2014; 111: 9591–9596. · DOI · Paper page
  59. Wang W, Ye C, Liu J, Zhang D, Kimata JT, Zhou P . CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PloS One 2014; 9: e115987. · DOI · Paper page
  60. Li C, Guan X, Du T, Jin W, Wu B, Liu Y et al. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. J Gen Virol 2015; 96: 2381–2393. · DOI · Paper page
  61. Zhu W, Lei R, Le Duff Y, Li J, Guo F, Wainberg MA et al. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology 2015; 12: 22. · DOI · Paper page
  62. Kaminski R, Bella R, Yin C, Otte J, Ferrante P, Gendelman HE et al. Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study. Gene Ther 2016; 23: 696. · DOI
  63. Wang G, Zhao N, Berkhout B, Das AT . CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape. Mol Ther 2016; 24: 522–526. · DOI · Paper page
  64. Wang Z, Pan Q, Gendron P, Zhu W, Guo F, Cen S et al. CRISPR/Cas9-derived mutations both inhibit HIV-1 replication and accelerate viral escape. Cell Rep 2016; 15: 481–489. · DOI · Paper page
  65. Yoder KE, Bundschuh R . Host double strand break repair generates hiv-1 strains resistant to CRISPR/Cas9. Sci Rep 2016; 6: 29530. · DOI
  66. Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 2014; 159: 440–455. · DOI · Paper page
  67. Mansouri M, Bellon-Echeverria I, Rizk A, Ehsaei Z, Cianciolo Cosentino C, Silva CS et al. Highly efficient baculovirus-mediated multigene delivery in primary cells. Nat Commun 2016; 7: 11529. · DOI
  68. Zuckermann M, Hovestadt V, Knobbe-Thomsen CB, Zapatka M, Northcott PA, Schramm K et al. Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. Nat Commun 2015; 6: 7391. · DOI · Paper page
  69. Wang L, Hao Y, Li H, Zhao Y, Meng D, Li D et al. Co-delivery of doxorubicin and siRNA for glioma therapy by a brain targeting system: angiopep-2-modified poly(lactic-co-glycolic acid) nanoparticles. J Drug Target 2015; 23: 832–846. · DOI
  70. Wang M, Zuris JA, Meng F, Rees H, Sun S, Deng P et al. Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proc Natl Acad Sci USA 2016; 113: 2868–2873. · DOI · Paper page
  71. Qazi S, Miettinen HM, Wilkinson RA, McCoy K, Douglas T, Wiedenheft B . Programmed self-assembly of an active P22-Cas9 nanocarrier system. Mol Pharm 2016; 13: 1191–1196. · DOI
  72. Bickel U, Kang YS, Yoshikawa T, Pardridge WM . In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem 1994; 42: 1493–1497. · DOI
  73. Yoshikawa T, Pardridge WM . Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor. J Pharmacol Exp Ther 1992; 263: 897–903. · DOI
  74. Zhang Y, Boado RJ, Pardridge WM . In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. J Gene Med 2003; 5: 1039–1045. · DOI
  75. Clark AJ, Davis ME . Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core. Proc Natl Acad Sci USA 2015; 112: 12486–12491. · DOI · Paper page
  76. De Luca MA, Lai F, Corrias F, Caboni P, Bimpisidis Z, Maccioni E et al. Lactoferrin- and antitransferrin-modified liposomes for brain targeting of the NK3 receptor agonist senktide: preparation and in vivo evaluation. Int J Pharm 2015; 479: 129–137. · DOI
  77. Tomitaka A, Arami H, Gandhi S, Krishnan KM . Lactoferrin conjugated iron oxide nanoparticles for targeting brain glioma cells in magnetic particle imaging. Nanoscale 2015; 7: 16890–16898. · DOI
  78. Fornaguera C, Dols-Perez A, Caldero G, Garcia-Celma MJ, Camarasa J, Solans C . PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood-brain barrier. J Control Release 2015; 211: 134–143. · DOI · Paper page
  79. Huang Y, Zhang B, Xie S, Yang B, Xu Q, Tan J et al. Modified with Tween 80 pass through the intact blood-brain barrier in rats under magnetic field. ACS Appl Mater Interfaces 2016; 8: 11336–11341. · DOI
  80. Kaushik A, Jayant RD, Nikkhah-Moshaie R, Bhardwaj V, Roy U, Huang Z et al. Magnetically guided central nervous system delivery and toxicity evaluation of magneto-electric nanocarriers. Sci Rep 2016; 6: 25309. · DOI
  81. Nair M, Guduru R, Liang P, Hong J, Sagar V, Khizroev S . Externally controlled on-demand release of anti-HIV drug using magneto-electric nanoparticles as carriers. Nat Commun 2013; 4: 1707. · DOI · Paper page
  82. Sagar V, Pilakka-Kanthikeel S, Atluri VS, Ding H, Arias AY, Jayant RD et al. Therapeutical neurotargeting via magnetic nanocarrier: implications to opiate-induced neuropathogenesis and neuroAIDS. J Biomed Nanotechnol 2015; 11: 1722–1733. · DOI
  83. Jayant RD, Atluri VS, Agudelo M, Sagar V, Kaushik A, Nair M . Sustained-release nanoART formulation for the treatment of neuroAIDS. Int J Nanomed 2015; 10: 1077–1093. · DOI

Cited by

See all 30

Metadata

Authors
Huang, Z., Tomitaka, A., Raymond, A., & Nair, M.
Venue
Gene Therapy
Published
2017-06-01
Volume
24
Issue
7
Pages
377-384
ISSN
  • 0969-7128
  • 1476-5462
Cited by
30
References
17
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current application of CRISPR/Cas9 gene-editing technique to eradication of HIV/AIDS. https://app.cochat.ai/papers/10.1038/gt.2017.35
The paper
Huang, Z., Tomitaka, A., Raymond, A., & Nair, M. (2017). Current application of CRISPR/Cas9 gene-editing technique to eradication of HIV/AIDS. Gene Therapy. https://doi.org/10.1038/gt.2017.35

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.